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Abstract
Background: Treatment of retained products of conception (RPOC) can be expectant, medical or operative.
Surgical removal of RPOC may lead to intrauterine adhesions (IUA) and Asherman’s syndrome.
Objective: To evaluate how treatment options for RPOC affect future fertility by means of a systematic review.
Search strategy: MEDLINE, EMBASE, The Cochrane Library, and clinical trial registers were searched, and reference
lists were scanned.
Selection criteria: Randomised controlled trials (RCT) comparing different treatment options for RPOC
(conservative, medical or surgical treatment, including curettage and/or hysteroscopic techniques, with or without
application of anti-adhesion therapy), in women of reproductive age, were eligible for inclusion.
Data collection and analysis: Reviewers independently performed data extraction and quality of evidence
assessment. For dichotomous variables, results were presented as risk ratio (RR) with 95% CI.
Main results: Two studies were included. Nonsignificant differences were observed between the use of an anti-
adhesion barrier gel versus no treatment after operative hysteroscopy in IUAs (RR 0.32, 95% CI 0.04 to 2.80, P value
= 0.30) and clinical pregnancy (RR 2.22, 95% CI 0.67 to 7.42, P value = 0.19), and between hysteroscopic morcellation
versus loop resection in IUAs (RR 0.86, 95% CI 0.06 to 13.12, P value = 0.91).
Conclusion: There is insufficient evidence on how different treatment options for RPOC affect future reproductive
outcomes. Results from ongoing RCTs are needed to guide clinicians towards choosing the best treatment.
Keywords: Retained products of conception, Treatment, Fertility, Reproductive outcome, Systematic review
Introduction
Retained products of conception (RPOC) consist of intra-
uterine tissue that develops after conception and persists
after miscarriage, termination of pregnancy, delivery or
caesarean section [1]. The occurrence of RPOC is not rare;
however, the prevalence varies widely (from 0.5 to as
much as 19%) depending on pregnancy duration, preg-
nancy outcome and the successive management [2]. There
is no consensus in literature on the type of tissue RPOC
comprise. Some authors describe RPOC as non-villous
trophoblastic tissue, chorionic villi or foetal membranes,
and they state that decidua alone does not fall within the
definition [3–5]. Others say that RPOC consist of the ges-
tational sac, the decidua capsularis, chorionic villi or the
embryo itself [6]. Still others argue that RPOC are from
placental origin, and thus, that the presence of chorionic
villi in RPOC is necessary [1, 7].
The diagnosis of RPOC remains a clinical challenge.
The existence of RPOC may be suspected based on clin-
ical history, with patients having symptoms of vaginal
bleeding, abdominal or pelvic pain, and/or fever. How-
ever, RPOC may also be present in asymptomatic pa-
tients [8]. Ultrasound (US) findings such as a thickened
endometrial echo complex or the presence of an endo-
metrial mass with or without detectable vascularity at
colour or power Doppler US are highly suggestive for
RPOC [1]. Still, there is no consensus on the US criteria,
and US alone may not be sensitive and/or specific
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enough to confirm the presence or absence of RPOC [1].
In order to avoid unnecessary procedures, diagnostic
hysteroscopy may be of additional value to ultrasonog-
raphy, although this needs further research [9, 10].
In case expectant management or medical treatment
of RPOC fails, the surgical treatment traditionally con-
sists of dilation and curettage, preferably under US guid-
ance, using vacuum aspiration and/or a metal curette.
Nevertheless, operative hysteroscopy is a suitable alter-
native to ‘blind’ curettage in the treatment of RPOC [5,
11–16]. These surgical procedures for RPOC, however,
expose the uterus to additional trauma, which can cause
intrauterine adhesions (IUAs) and Asherman’s syn-
drome, clinically manifested by menstrual abnormalities,
infertility and recurrent pregnancy loss [17].
The objective of the present study was to evaluate how
the different treatment options for RPOC affect future
fertility.
Methods
We specified the methods in advance and registered the
protocol of the review on PROSPERO (CRD42016042444).
We followed the PRISMA guidelines for writing a systematic
review.
Criteria for selecting studies for this review
Types of studies
Published parallel-group randomised controlled trials
(RCTs) were eligible for inclusion. Non-randomised
studies (e.g. studies with evidence of inadequate se-
quence generation such as alternate days, participant
numbers) were excluded, as they are associated with a
high risk of bias.
Types of participants
Women of reproductive age with RPOC more than 24 h
after end of pregnancy, without the presence of gesta-
tional trophoblastic disease or uterine malignancies. Tri-
als that excluded women who wished to conceive were
not eligible.
Types of interventions
We included the following randomly assigned comparisons:
– Expectant management versus medical treatment
– Expectant management versus surgical removal by
curettage or hysteroscopy
– Medical treatment versus surgical removal by
curettage or hysteroscopy
– Curettage versus hysteroscopy
– Technique A versus technique B for operative
hysteroscopy
– Anti-adhesion therapy versus placebo or no
treatment following surgical treatment
The last two comparisons were not pre-defined in our
review protocol. We included these randomised compar-
isons because at present different hysteroscopic tech-
niques are available for the treatment of RPOC and
anti-adhesion therapy following surgical treatment of
RPOC may affect subsequent reproductive outcome
[18]. The findings of our review might be biased if these
two comparisons were omitted.
Types of outcome measures
Primary outcomes:
– Live birth rate. Live birth was defined as the
complete expulsion or extraction from its mother of
a product of fertilisation, irrespective of the duration
of the pregnancy, which, after such separation,
breathes or shows any other evidence of life, such as
heart beat, umbilical cord pulsation, or definite
movement of voluntary muscles, irrespective of
whether the umbilical cord has been cut or the
placenta is attached. We count the delivery of
singleton, twin or multiple pregnancies as one live
birth.
– Presence of IUAs at second-look hysteroscopy.
Secondary outcomes:
– Time to conception, conception rate and clinical
pregnancy rate. Clinical pregnancy was defined as a
pregnancy diagnosed by ultrasonographic
visualisation of one or more gestational sacs or
definitive clinical signs of pregnancy. It includes
ectopic pregnancy. Multiple gestational sacs are
counted as one clinical pregnancy.
– Miscarriage rate. Miscarriage was defined as the
spontaneous loss of a clinical pregnancy before 20
completed weeks of gestational age (18 weeks after
fertilisation) or, if gestational age is unknown, the
loss of an embryo/foetus of less than 400 g.
Eligible studies that could have measured the out-
comes of interest were reviewed and any lack of data for
the key outcomes was reported in the final review. We
adhered as much as possible to terminology of the Inter-
national Committee for Monitoring Assisted Reproduct-
ive Technology (ICMART) (http://www.icmartivf.org/)
for key reproductive outcomes (live birth, pregnancy and
miscarriage) [19]. We contacted primary study authors
for clarification in cases of unclear definitions. We re-
ported discrepancies or uncertainties in the final review.
Search methods for identification of studies
The following electronic bibliographic databases were
searched: MEDLINE, EMBASE, and The Cochrane
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Library (Cochrane Central Register of Controlled Trials
(CENTRAL)). The search strategy included terms relat-
ing to or describing the disease (retained products of
conception), management or intervention (expectant,
medical or surgical) and outcome (fertility). The search
terms were adapted for use to each bibliographic database,
and a combination of both MeSH/Emtree and free-text
terms was used (Additional file 1: Appendix S1). There
were no language restrictions in the search, but we in-
cluded only articles in English, French, German, Dutch,
Italian and Portuguese, due to restraints in time and cost.
In addition, the reference lists of eligible studies were
scanned, and clinical trial registers were searched for on-
going and registered trials (World Health Organization
(WHO) International Clinical Trials Registry Platform
(ICTRP) search portal (http://apps.who.int/trialsearch/)
and ClinicalTrials.gov (https://clinicaltrials.gov)).
Data collection and analysis
Selection of studies
Duplicates of the studies obtained by the search strategy
were removed using specialised software (EndNote X7).
The titles and abstracts of the remaining studies were
screened independently and simultaneously by two review
authors (D.M., H.V.d.V.). The full texts of the potentially
eligible studies were retrieved and independently assessed
by the same two review team members for compliance
with the inclusion criteria, and studies eligible for inclu-
sion in the review were selected. Any disagreement during
the selection was resolved through discussion or, if re-
quired, by consulting a third and/or fourth review author
(T.H., S.W.).
Data extraction and management
A pre-piloted form (Additional file 2: Appendix S2) was
used by two review authors (T.H., H.V.d.V.) independ-
ently to extract data from the included studies for as-
sessment of study quality and evidence synthesis.
Discrepancies were identified and resolved through dis-
cussion, with a third and/or fourth author (J.B., S.W.)
where necessary. When information regarding an essen-
tial topic was missing or unclear, contact with the au-
thors was attempted.
Assessment of risk of bias in included studies
Risk of bias of the included studies was independently
assessed by two authors (T.H., H.V.d.V.) according to the
Cochrane risk of bias assessment (random sequence gen-
eration, allocation concealment, blinding of participants
and personnel, blinding of outcome assessment, incom-
plete outcome data, selective outcome reporting and other
potential sources of bias) [20]. Disagreements between the
review authors over the risk of bias in particular studies
were resolved by discussion, with involvement of a third
review author (J.B.) where necessary.
Measures of treatment effect
For dichotomous outcomes, we used risk ratios (RR)
with 95% confidence intervals (CI).
Data synthesis
Statistical analysis was performed using the software RE-
VIEW MANAGER 5.3 provided by the Cochrane Col-
laboration [21]. For dichotomous variables, results were
presented as RR with 95% CI. We aimed to perform stat-
istical pooling if enough studies were retrieved. However,
in case of clinical diversity or evidence of substantial
statistical heterogeneity, we provided a narrative synthe-
sis of the findings rather than statistical pooling.
Results
Description of studies
A total of 777 citations were identified from searching
electronic databases and trial registers, of which 185 du-
plicate citations were removed. The remaining 592 re-
cords were assessed for eligibility through checking the
titles and/or abstracts. We excluded 567 records as be-
ing obviously irrelevant. The eligibility of the remaining
25 articles was assessed by reading the full text. We re-
trieved six potentially eligible studies, we included two
randomised trials (Additional file 3: Table S1), one was ex-
cluded (Additional file 4: Table S2) and three studies are
ongoing (NCT02201732, NTR4923, ChiCTR-INR-16009
074) (Additional file 5: Table S3). The PRISMA flow chart
for study selection is shown in Fig. 1.
We included two parallel-design RCTs [10, 22]. The
first trial was performed in a tertiary medical care centre
in Israel [22]. Fifty-two women underwent hysteroscopic
surgery because of suspected RPOC. The mean age was
29.5 years (standard deviation (SD) 5.1 years) in the
intervention group and 31.4 years (SD 6.5 years) in the
control group. The trial did not include women with pri-
mary subfertility. After hysteroscopic removal of RPOC,
a viscoelastic gel, composed of polyethylene oxide and
carboxymethylcellulose, was applied or not. All patients
received postoperative sequential hormone treatment
and antibiotics. The outcomes were clinical pregnancy
and presence of IUAs. The second trial was a multicen-
tre study from Belgium and the Netherlands [10].
Eighty-six women who underwent hysteroscopic surgery
because of RPOC were included. The mean age was
32 years (SD 6 years) in the hysteroscopic morcellation
group and 31 years (SD 4 years) in the loop resection
group. RPOC were removed by hysteroscopic morcella-
tion or loop resection. In the resection group, cold loop
resection was attempted first, whereas the loop was elec-
trically activated in case the RPOC were too adherent to
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be removed by cold loop (4/39 cases, 10%). Patients did
not receive any cervical ripening agents or standard anti-
biotic prophylaxis preoperatively. The outcome was the
presence of IUAs.
Risk of bias in included studies
See: assessment of the risk of bias (Additional file 6:
Table S4) and Fig. 2. We judged both trials to be at low
risk for selection bias related to random sequence gener-
ation and allocation, because a computer-generated ran-
domisation list and sequentially numbered opaque
sealed envelopes were used. We judged both trials to be
at low risk of performance and detection bias in relation
to blinding of participants, personnel and outcome as-
sessors for the outcome of clinical pregnancy, because
clinical pregnancy is an unequivocal outcome. For the
outcome of presence of IUAs, we considered both trials
to be at high risk of performance bias in relation to
blinding of participants and personnel, because
personnel were not blinded in the trial of Fuchs et al.
and participants and personnel were not blinded in the
trial of Hamerlynck et al. We found the trial of Fuchs et
al. to be at low risk of detection bias for the key outcome
of IUAs because outcome assessors were independent
observers blinded to treatment allocation. However, we
found the trial of Hamerlynck et al. to be at high risk of
detection bias for the outcome of IUAs because outcome
assessors were aware of the treatment allocation. We
judged the trial of Fuchs et al. to be at high risk of attri-
tion bias, because a high proportion of women were ex-
cluded after randomisation (11/52 or 21%) without
clarification of the reasons. Similarly, in the trial of
Hamerlynck et al., 9 of 44 participants and 6 of 39 par-
ticipants undergoing hysteroscopic removal of placental
remnants did not undergo second-look hysteroscopy
(15/83 or 18%), leading to a high risk of attrition bias.
We considered the trial of Fuchs et al. to be at high risk
of selective reporting, because it failed to report data for
the primary outcome of live birth despite a study dur-
ation of 27 months. The trial of Hamerlynck et al. was
considered to be at low risk of selective reporting,
Fig. 1 Study flow diagram
Fig. 2 Risk of bias summary
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because all pre-specified outcomes were reported. We
found the trial of Fuchs et al. to be at high risk of other
potential sources of bias, because at follow-up hysteros-
copy co-treatment with hysteroscopic adhesiolysis was
offered to women with AFS II or III IUAs. The differ-
ences in co-treatment between both comparison
groups—three of 20 (14%) women in the control group
and one of 21 (4%) women in the intervention group—
may have affected the extent and course of the treatment
effect. Similarly, in the trial of Hamerlynck et al., adhe-
siolysis was offered to women with IUAs, leading to a
potential source of bias in relation to fertility outcome.
Effects of interventions
We retrieved no randomised studies for the comparisons
of expectant management versus medical treatment or
surgical removal, medical treatment versus surgical re-
moval, or curettage versus hysteroscopy for the treat-
ment of RPOC.
We found one randomised trial comparing anti-adhesion
therapy with no treatment following surgical treatment
[22]. There was no evidence of a statistically significant dif-
ference between both comparison groups for the outcome
of IUAs at second-look hysteroscopy at 5 to 8 weeks (RR
0.32, 95% CI 0.04 to 2.80, P value = 0.30, one study, 41
women; Fig. 3). There were no statistically significant
differences in clinical pregnancy rates between both
comparison groups (RR 2.22, 95% CI 0.67 to 7.42, P
value = 0.19, 1 study, 41 women; Fig. 3). We retrieved
one randomised trial comparing hysteroscopic morcel-
lation with loop resection for removal of RPOC [10].
There was no evidence of a statistically significant dif-
ference between both comparison groups for the out-
come of de novo IUAs at second-look hysteroscopy at
6 to 8 weeks (RR 0.86, 95% CI 0.06 to 13.12, P value
= 0.91, 1 study, 65 women; Fig. 4).
Discussion
Main findings
Our systematic review aimed at investigating the influ-
ence of the treatment of RPOC on reproductive out-
come and the presence of IUAs. We searched for
randomised trials comparing different treatment options
(expectant management, medical and surgical treatment)
for women of reproductive age with RPOC more than
24 h after end of pregnancy, in relation to fertility and/
or the presence of IUAs.
We found only one randomised study containing 41
participants on the use of an anti-adhesion barrier gel
versus no treatment after hysteroscopic treatment of
RPOC and one randomised study containing 86 partici-
pants on hysteroscopic morcellation versus loop resec-
tion for removal of RPOC [10, 22]. Both studies had a
high risk of bias on four out of seven items. According
to the results of both studies, there is no evidence of sta-
tistically significant differences between both compari-
son groups for the outcomes of clinical pregnancy or the
presence of IUAs at second-look hysteroscopy.
Strengths and limitations
We aimed to follow the guidelines recommended by the
Cochrane Handbook as much as possible [20]. We ex-
cluded non-randomised studies to minimise bias. We
aimed at investigating the influence of the treatment of
RPOC on fertility. Selection of studies and extraction of
data was performed by two review authors independently.
Only two relevant randomised studies were identified.
The studies were at high risk of bias, so results should
be interpreted with caution, and they did not report on
the primary outcome of live birth. However, for the trial
performed by our group, we are considering follow-up
of reproductive outcome for the patients as randomised
[10]. Moreover, in the trial that did report on pregnancy,
relevant information was lacking regarding the histologic
1.1 Presence of intrauterine adhesions at second-look hysteroscopy 
1.2 Clinical pregnancy 
Fig. 3 Forest plot of comparison: 1 gel versus no treatment
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criteria for RPOC, absolute numbers of pathologic con-
firmation of RPOC per group, the relation between
histologic confirmation of RPOC and/or IUAs and/or
fertility, as well as the number of women actually trying
to reconceive after treatment of RPOC [22]. Our query
related to these topics remained unanswered by the
authors.
Interpretation
Previous reviews have addressed the topic of reproduct-
ive outcome after treatment of RPOC [23, 24]. Both re-
views identified only cohort studies and no randomised
trials. The trials included in the reviews studied the
treatment of RPOC by curettage, hysteroscopy or both.
The results in relation to IUAs appear to be in favour of
hysteroscopic treatment of RPOC; however, no signifi-
cant differences in conception or ongoing pregnancy
rates were demonstrated. Due to the low methodological
quality and high risk of bias in the included cohort stud-
ies—although a formal assessment of the risk of bias was
lacking in both reviews—, the results need to be inter-
preted with caution. Our review was limited to rando-
mised trials in order to reduce the risk of bias. We could
identify one randomised trial examining the use of an
anti-adhesion barrier after operative hysteroscopy for
RPOC [22]. The study did not show a significant differ-
ence in the presence of IUAs or clinical pregnancy rate
between intervention and control group. This finding is
in line with the results of the systematic review of Bos-
teels et al. stating that the effectiveness of anti-adhesion
therapy in improving reproductive outcome or reducing
IUAs following operative hysteroscopy in subfertile
women is still unclear [18]. The second study identified
was a randomised trial comparing two hysteroscopic
techniques, namely, hysteroscopic morcellation with
loop resection for removal of RPOC [10]. The trial did
not show a significant difference in the presence of
IUAs. However, both identified trials may have been too
small to demonstrate a difference in the outcome mea-
sures, and other factors than the techniques under study
may have contributed to the risk of IUA formation or in-
fluenced the reproductive outcome.
Conclusions
Implication for practice
For daily clinical practice, the effectiveness of anti-adhesion
treatment in improving key reproductive outcomes or de-
creasing IUAs following operative hysteroscopy for RPOC
in women wishing to conceive remains uncertain. Similarly,
it is not clear whether hysteroscopic morcellation or loop
resection of RPOC leads to better reproductive outcomes
or a lower risk of IUAs.
Implication for research
Additional studies are needed to evaluate the influence
of RPOC on fertility. Hypothetically, there may be causal
mechanisms linking the risk for RPOC with adverse re-
productive outcomes such as infertility and recurrent
miscarriage. The diagnostic modalities for RPOC need
to be evaluated, and histopathological definitions need
to be reviewed, aiming at reaching a consensus and pro-
viding practical guidelines. Different treatment modal-
ities including expectant management, medical and
surgical treatment (curettage, different hysteroscopic
techniques) need to be compared to study reproductive
outcome and cost-effectiveness. The size of the study
population needs to be sufficiently large, and follow-up
should be long enough to study the outcomes of interest.
Obstetric history and other factors related to the occur-
rence of RPOC as well as the development of IUAs need
to be considered when performing research on the sub-
ject. Our RCT, included in this review, should be consid-
ered as a pilot trial for hypothesis testing. Our future
research agenda includes a pragmatic multicentre trial
studying IUAs and reproductive outcome after surgical
treatment of RPOC (NTR4923). Hysteroscopic morcella-
tion (TRUCLEAR) is compared with US guided electric
vacuum aspiration, because the latter is still the most fre-
quently applied treatment for RPOC in Belgium and the
Netherlands. There are currently two other ongoing trials
examining following comparisons for treatment of RPOC:
operative hysteroscopy (resection) versus vacuum aspiration
(NCT02201732; primary outcome: intrauterine pregnancy
lasting up to at least 22 weeks of gestation), and hystero-
scopic morcellation (MyoSure) versus hysteroscopic
2.1 Presence of intrauterine adhesions at second-look hysteroscopy 
HM = hysteroscopic morcellation; LR = loop resection 
Fig. 4 Forest plot of comparison: 2 hysteroscopic morcellation versus loop resection
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monopolar loop resection (ChiCTR-INR-16009074; second-
ary outcomes: IUAs and pregnancy rate).
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